Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

ESSA Pharma And 2 Other Penny Stocks Insiders Are Aggressively Buying

Published 21/07/2022, 13:27
© Reuters.  ESSA Pharma And 2 Other Penny Stocks Insiders Are Aggressively Buying
IXIC
-
EPIX
-

Tesla Inc (NASDAQ: TSLA) posted better-than-expected earnings for its second quarter, while sales missed estimates. Investors, meanwhile, focused on some notable insider trades.

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.3

Great Elm Group

  • The Trade: Great Elm Group, Inc. (NASDAQ: GEG) 10% owner Long Ball Partners LLC acquired a total of 6,951 shares at an average price of $1.99. To acquire these shares, it cost around $13.84 thousand.
  • What’s Happening: Great Elm Group, last month, priced public offering of $25,000,000 of 7.25% notes due 2027.
  • What Great Elm Group Does: Great Elm Group Inc formerly, Great Elm Capital Group Inc operates as a holding company.
Helbiz
  • The Trade: Helbiz, Inc. (NASDAQ: HLBZ) CEO Salvatore Palella acquired a total of 327,425 shares at an average price of $0.62. The insider spent around $203.99 thousand to buy those shares.
  • What’s Happening: Helbiz recently released the HelmetChecker, a real-time AI helmet verification, for sale to micro-mobility operators.
  • What Helbiz Does: Helbiz Inc provides electric micro-mobility services. The company offers a diverse fleet of vehicles including e-scooters, e-bicycles and e-mopeds all on one convenient, user-friendly platform around the world.
Bitcoin, Ethereum Record Losses, Here Are The Top Crypto Movers For Thursday

Don’t forget to check out our premarket coverage here .

ESSA Pharma

  • The Trade: ESSA Pharma Inc. (NASDAQ: EPIX) 10% owner BB Biotech AG acquired a total of 300,000 shares at an average price of $3.16. To acquire these shares, it cost around $946.74 thousand.
  • What’s Happening: ESSA Pharma, last month, presented clinical results from the Phase 1a dose-escalation study of EPI-7386 as a monotherapy for metastatic castration-resistant prostate cancer (mCRPC) resistant to current standard-of-care therapies.
  • What ESSA Pharma Does: ESSA Pharma Inc is a pharmaceutical company. The company is in the preclinical stage, focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.